Passage Bio reports 2025 net loss of $45.5M; cash runway through Q1 2027; advances FTD clinical program

Passage BIO, Inc.

Cash and cash equivalents $46.3M at Dec 31, 2025; funding expected through Q1 2027.
Net loss of $45.5M ($14.35/diluted share) for 2025, improved from $64.8M ($21.04/sh) in 2024.
R&D expenses $23.3M in 2025, down from $40.2M in 2024; G&A $19.9M vs $25.0M.
Enrolled first 3 FTD-GRN patients in Cohort 3; dosed first FTD-C9orf72 patient with Dose 2 PBFT02 in Cohort 4.
Expects interim safety/biomarker data and regulatory feedback on FTD-GRN registrational trial in 1H 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.